A phase II study of cabozantinib and pembrolizumab in advanced gastric/gastroesophageal adenocarcinomas resistant or refractory to immune checkpoint inhibitors.
- Published in:
- Oncologist, 2024, v. 29, n. 8, p. 721, doi. 10.1093/oncolo/oyae117
- By:
- Publication type:
- Article